Renaissance Technologies’s Metagenomi Therapeutics MGX Stock Holding History

Renaissance Technologies’s Portfolio MGX Stock Details MGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$883K	Sell	742,400 -45,500	-6%	-$60.9K	﹤0.01%	2370
2026 Q1	$1.06M	Buy	787,900 +159,500	+25%	+$248K	﹤0.01%	2243
2025 Q4	$1.02M	Buy	628,400 +461,400	+276%	+$999K	﹤0.01%	2272
2025 Q3	$396K	Buy	167,000 +48,000	+40%	+$97.4K	﹤0.01%	2886
2025 Q2	$176K	Buy	119,000 +19,400	+19%	+$30.4K	﹤0.01%	3195
2025 Q1	$135K	Sell	99,600 -54,200	-35%	-$129K	﹤0.01%	3149
2024 Q4	$555K	Sell	153,800 -28,300	-16%	-$68.3K	﹤0.01%	2794
2024 Q3	$395K	Buy	+182,100	New	+$632K	﹤0.01%	2881

Other funds holding MGX

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

CCM

Catalio Capital Management New York $532M AUM 171.17% 1-Year Est. Return

PLC

Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

PVI

Pura Vida Investments New York $37M AUM 63.54% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Renaissance Technologies's MGX Position: Q2 2026 in Review

Renaissance Technologies reduced its Metagenomi Therapeutics (MGX) stake by 5.8% in Q2 2026, selling an estimated $60.9K and leaving 742,400 shares worth $883K. The position accounts for ﹤0.01% of the portfolio, ranked #2370.

Renaissance Technologies first reported a position in MGX in Q3 2024 and has held it in 8 quarters since. The position peaked at $1.06M in Q1 2026. 43 funds tracked by Wall St. Rank hold MGX as of Q2 2026.

Renaissance Technologies held 742,400 shares of Metagenomi Therapeutics worth $883K as of Q2 2026.
Renaissance Technologies sold 45,500 Metagenomi Therapeutics shares in Q2 2026, an estimated $60.9K.
Metagenomi Therapeutics made up ﹤0.01% of Renaissance Technologies's portfolio in Q2 2026, its #2370 holding.
Renaissance Technologies first reported a position in Metagenomi Therapeutics in Q3 2024 and has held it in 8 quarters since.
Renaissance Technologies's Metagenomi Therapeutics position peaked at $1.06M in Q1 2026.
43 funds tracked by Wall St. Rank held Metagenomi Therapeutics as of Q2 2026.

Based on Renaissance Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.